SCYNEXIS (NASDAQ:SCYX) Stock Passes Above 50-Day Moving Average of $2.53

view original post

SCYNEXIS, Inc. (NASDAQ:SCYXGet Rating)’s stock price crossed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $2.53 and traded as high as $2.70. SCYNEXIS shares last traded at $2.59, with a volume of 67,850 shares traded.

SCYNEXIS Price Performance

The stock has a market capitalization of $84.57 million, a P/E ratio of -1.62 and a beta of 2.00. The company has a current ratio of 7.85, a quick ratio of 7.81 and a debt-to-equity ratio of 0.98. The company has a fifty day simple moving average of $2.53 and a two-hundred day simple moving average of $2.70.

SCYNEXIS (NASDAQ:SCYXGet Rating) last announced its quarterly earnings data on Monday, August 15th. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.04. The firm had revenue of $1.32 million during the quarter, compared to analysts’ expectations of $1.18 million. SCYNEXIS had a negative return on equity of 169.86% and a negative net margin of 1,557.60%. During the same period in the previous year, the business posted ($0.22) EPS. Sell-side analysts expect that SCYNEXIS, Inc. will post -1.97 EPS for the current fiscal year.

Institutional Trading of SCYNEXIS

Institutional investors and hedge funds have recently modified their holdings of the stock. DAFNA Capital Management LLC bought a new stake in shares of SCYNEXIS in the 4th quarter valued at about $740,000. D.A. Davidson & CO. increased its stake in shares of SCYNEXIS by 2.0% in the 1st quarter. D.A. Davidson & CO. now owns 293,840 shares of the company’s stock valued at $1,149,000 after acquiring an additional 5,755 shares during the last quarter. Worth Venture Partners LLC increased its stake in shares of SCYNEXIS by 13.8% in the 1st quarter. Worth Venture Partners LLC now owns 560,517 shares of the company’s stock valued at $2,192,000 after acquiring an additional 67,788 shares during the last quarter. State Street Corp increased its stake in shares of SCYNEXIS by 9.3% in the 1st quarter. State Street Corp now owns 78,630 shares of the company’s stock valued at $307,000 after acquiring an additional 6,694 shares during the last quarter. Finally, Chicago Partners Investment Group LLC increased its stake in shares of SCYNEXIS by 20.4% in the 1st quarter. Chicago Partners Investment Group LLC now owns 50,192 shares of the company’s stock valued at $106,000 after acquiring an additional 8,517 shares during the last quarter. 50.03% of the stock is owned by institutional investors.

About SCYNEXIS

(Get Rating)

SCYNEXIS, Inc, a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC).

Featured Articles

Receive News & Ratings for SCYNEXIS Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for SCYNEXIS and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts